Vilon Research

Vilon is a synthetic dipeptide, lysyl-glutamic acid, written Lys-Glu or KE, and it is the smallest defined molecule in the Khavinson peptide family. The sequence is stated in the peer-reviewed record ^[1], and PubChem lists it as CID 7010502, CAS 45234-02-4, formula C11H21N3O5. A table in the developer group's own review lists Vilon and Normoftal as separate rows with different docking scores, although NLM and PubChem treat them as the same molecule ^[19].

Vilon is a defined molecule, not an extract, and its parent preparation Thymalin is an undefined polypeptide complex from calf thymus. The originating group describes the KE and EW dipeptides as active substances of Thymalin ^[2]. That attribution comes from the group's own docking and cell-culture paper, not from a compositional analysis of the extract ^[2]. Because Thymalin is an extract and Vilon is a defined molecule, evidence about one does not transfer to the other.

Nearly all research on this compound comes from one commercial programme. Vilon

The literature is not independent

Vladimir Khavinson directs the St Petersburg Institute of Bioregulation and Gerontology, which developed, patented and sells these peptides. The great majority of indexed Vilon papers carry Khavinson or his long-term collaborators as authors ^[3]. The compounds enter the literature under the registered trademarks Vilon and Khavinson Peptides ^[4]. The only systematic review of this peptide class indexed on PubMed was written by the developer group itself, and it declares no conflict of interest ^[5].

No unaffiliated laboratory has published a replication of any Vilon finding, and volume is not corroboration. The nearest apparent exception, the Tbilisi group whose chromatin work appears below, co-authored a 2004 Vilon paper with Khavinson, indexed under the misspelled surname Khavison ^[22]. Treat every claim below as originator-generated.

Animal findings, including an adverse one

The most consequential animal result for Vilon is negative. In female HER-2/neu transgenic mice, Vilon significantly increased mammary cancer incidence, shortened the mean latent period and increased the cumulative number of tumors ^[6]. Epitalon, tested in the same experiment, reduced tumor number and size ^[6]. The developer group published this in a mainstream international journal, and vendor material rarely mentions it.

The direction of effect reverses in a different model. In a rat bladder carcinogenesis study, Vilon was reported to lower tumor incidence to 56 percent against 75.5 percent in controls, while Epitalon showed no inhibitory effect ^[7]. Both are animal studies, and together they show only that these peptides are not interchangeable.

Two PubMed-indexed animal reports claim Vilon prolongs lifespan in mice ^[8]. Neither supports a stated effect size: one is a short note with no abstract, methods or sample size in the record, and the other does not quantify the effect ^[8]. A separate mouse study reported that Lys-Glu did not significantly change body weight, food consumption, free-radical measures or estrous function ^[9]. The same abstract reports that it did increase physical activity, with a subsequent decrease in spontaneous lung adenoma incidence ^[9].

The proposed DNA mechanism is mostly computational

This family is marketed on a proposed mechanism, that short peptides enter the nucleus and bind gene promoters, and for Vilon that case rests largely on molecular docking. A large in silico screen ranked KE first among the selective charged dipeptides, while finding that most dipeptides could not bind DNA at all ^[10]. Its only wet-lab step was a gel-shift assay run far above physiological peptide concentrations, and it reports no dissociation constant ^[10].

The predicted DNA target for KE is also unstable across papers from the same group. Different publications name different motifs, and in several the motif is shared with a second peptide rather than assigned to KE alone ^[11][12]. A recognition site that moves when the software changes is a property of the model.

Downstream cell data do exist, and Vilon has been reported to raise SIRT1 expression in cultured mesenchymal stem cells ^[12]. In organotypic spleen culture, Lys-Glu stimulated growth while a mixture of its free amino acids inhibited it ^[13]. These in vitro results show the molecule does something. They do not show it does it by binding DNA.

Work on human cells is ex vivo only. Applied to lymphocytes from donors aged 75 to 88, Vilon and three siblings each affected different chromosome regions, and none decondensed pericentromeric heterochromatin ^[14]. Cells taken from people are not people.

No NMR structure, crystal structure, or calorimetric or surface-plasmon binding measurement of Vilon with DNA has been published.

Human reports

Three Russian-language clinical reports name Vilon ^[15], covering coagulation in type 1 diabetes, immune status in elderly diabetic patients, and adjunct use in elderly colorectal cancer. PubMed indexes the first as a randomized controlled trial and the third as a controlled clinical trial ^[15]. None of the three reports sample size, randomization method, blinding or effect size in the retrievable abstract, and the oncology report calls itself pioneer experience with preliminary results ^[15]. No trial of Vilon is registered on ClinicalTrials.gov, where a search on the name returns one unrelated study, NCT02580799, a HER2 breast-cancer pathology project ^[16].

Absorption and pharmacokinetics

No human pharmacokinetic study of Vilon has been published, and no human peak concentration, half-life or clearance figure exists.

The mammary carcinogenesis study injected the peptide rather than feeding it ^[6]. PepT1, the intestinal transporter for small peptides, handles di- and tripeptides only ^[17], and Vilon is a dipeptide, so it is the right size. Nobody has tested whether it is actually a PepT1 substrate. Transport is also not systemic delivery, because gut peptidases hydrolyze much of what crosses. The one oral study gave Vilon to aged rats and measured the intestine's own transport capacity, never the peptide in blood ^[18]. That result is compatible with the peptide never leaving the gut intact.

What the literature does not say

Vilon (KE) is the N-terminal dipeptide of the whole KED series: Vesugen (KED), Livagen (KEDA), Testagen (KEDG), Prostamax (KEDP) and Pancragen ^[19]. That source's table spells Prostamax as Prostomax, so a reader text-searching it for the usual spelling finds nothing ^[19]. No published study explains what functionally separates Vilon from those siblings, and any stated difference would be invention. Elsewhere in this family a single residue change abolished activity in one animal model ^[20].

Anisimov, who generated much of this animal data, wrote that geroprotector evidence of this kind is scarce, contradictory and often not reliable ^[21]. He also noted that one class of geroprotector raised tumor incidence ^[21]. Vilon did that in the mammary study ^[6], though his review does not place Vilon in that class.

No marketing authorization for Vilon has been identified in the United States or the European Union. Nothing here describes a treatment or any use in people.

Frequently Asked Questions

Is there human evidence for Vilon? Three Russian-language clinical reports name Vilon ^[15], and none reports sample size, randomization method, blinding or effect size in the retrievable abstract. PubMed indexes one as a randomized controlled trial and another as a controlled clinical trial, and the oncology report calls itself preliminary ^[15]. No trial of Vilon is registered on ClinicalTrials.gov, where the only hit under that name is an unrelated breast-cancer study ^[16].

Has any outside laboratory confirmed these findings? No unaffiliated laboratory has published a replication of any Vilon finding, and the great majority of indexed Vilon papers carry Khavinson or his long-term collaborators as authors ^[3]. The only systematic review of this peptide class indexed on PubMed was written by the developer group itself ^[5]. The nearest apparent exception, the Tbilisi group, co-authored a 2004 Vilon paper with Khavinson ^[22].

Is Vilon the same thing as Thymalin? No, Vilon is a defined dipeptide, Lys-Glu ^[1]. Thymalin is an undefined polypeptide complex from calf thymus, and the originating group describes KE and EW as its active substances ^[2]. Because one is an extract and the other a defined molecule, evidence about one does not transfer to the other.

How does Vilon differ from Vesugen and the other KED peptides? The published literature does not answer this: Vilon is the N-terminal dipeptide of that whole series ^[19], and no study explains what functionally separates them. Elsewhere in this family a single residue change abolished activity in one animal model ^[20].

References

1. 1

   Kazakova TB, et al. (2002). Bulletin of Experimental Biology and Medicine. PMID 12447482.; DOI 10.1023/a:1020210615148.
2. 2

   Linkova N, et al. (2023). International Journal of Molecular Sciences. PMID 37686182.; DOI 10.3390/ijms241713377. PubMed publication type: Journal Article, not Review.
3. 3

   PubMed authorship analysis of the indexed Vilon literature, run 27 August 2026. Database query, no PMID or DOI.
4. 4

   Avolio F, et al. (2022). International Journal of Molecular Sciences. PMID 35408963.; DOI 10.3390/ijms23073607.
5. 5

   Khavinson VK, et al. (2021). Molecules. PMID 34834147.; DOI 10.3390/molecules26227053. PubMed publication type: Systematic Review; the record carries the declaration "The authors declare no conflict of interest."
6. 6

   Anisimov VN, et al. (2002). International Journal of Cancer. PMID 12209581.; DOI 10.1002/ijc.10570.
7. 7

   Pliss GB, et al. (2001). Voprosy Onkologii. PMID 11785104. (Russian language). English companion report: Bulletin of Experimental Biology and Medicine (2001). PMID 11586406.; DOI 10.1023/a:1012354603132.
8. 8

   Khavinson VKh, et al. (2000). Doklady Biological Sciences. PMID 10944717. And Khavinson VK, et al. (2000). Bulletin of Experimental Biology and Medicine. PMID 11140587.; DOI 10.1007/BF02682106.
9. 9

   Anisimov VN, et al. (2001). Mechanisms of Ageing and Development. PMID 11163623.; DOI 10.1016/s0047-6374(00)00184-6.
10. 10

    Kolchina N, et al. (2019). Nucleic Acids Research. PMID 31598715.; DOI 10.1093/nar/gkz850.
11. 11

    Khavinson VK, et al. (2016). Bulletin of Experimental Biology and Medicine. PMID 27909961.; DOI 10.1007/s10517-016-3596-7.
12. 12

    Khavinson VK, et al. (2023). Advances in Gerontology. PMID 37782636. (Russian language, no DOI assigned).
13. 13

    Khavinson VKh, et al. (2015). Bulletin of Experimental Biology and Medicine. PMID 25705040.; DOI 10.1007/s10517-015-2805-0.
14. 14

    Lezhava T, et al. (2023). Georgian Medical News. PMID 37042594. (no DOI assigned).
15. 15

    Kuznik BI, et al. (2006). Advances in Gerontology. PMID 17152731. (PubMed types: Journal Article, Randomized Controlled Trial). Kuznik BI, et al. (2007). Advances in Gerontology. PMID 18306698. (Clinical Trial). Ias'kevich LS, et al. (2005). Advances in Gerontology. PMID 16075684. (Clinical Trial, Controlled Clinical Trial). All Russian language, English abstracts only.
16. 16

    ClinicalTrials.gov registry query, run 27 August 2026. Registry query, no PMID or DOI. One name-collision hit, NCT02580799.
17. 17

    Spanier B (2018). Comprehensive Physiology. PMID 29687907.; DOI 10.1002/cphy.c170038. Terada T (2012). Current Topics in Membranes. PMID 23177989.; DOI 10.1016/B978-0-12-394316-3.00008-9.
18. 18

    Khavinson VKh, et al. (2002). Bulletin of Experimental Biology and Medicine. PMID 12420071.; DOI 10.1023/a:1019878224754.
19. 19

    Khavinson V, et al. (2022). International Journal of Molecular Sciences. PMID 35887081.; DOI 10.3390/ijms23147733.
20. 20

    Kuznik BI, et al. (2008). Advances in Gerontology. PMID 19432169. (Russian language, no DOI assigned).
21. 21

    Anisimov VN (2001). Experimental Gerontology. PMID 11404054.; DOI 10.1016/s0531-5565(01)00114-0.
22. 22

    Lezhava T, et al. (2004). Biogerontology. PMID 15105581.; DOI 10.1023/B:BGEN.0000025070.90330.7f. Khavinson is second author, indexed in the live record under the misspelling "Khavison V".